Eurazeo takes majority stake in D.O.R.C.
Context
Eurazeo Capital completed the acquisition of 100% of the share capital of D.O.R.C. from its previous owners. The transaction positions Eurazeo as the majority shareholder of a rapidly growing MedTech player in the dynamic ophthalmic surgery market. The strategic plan focuses on capitalizing on D.O.R.C.'s highly regarded brand and innovative technology to drive further international growth, with a specific priority on capturing market share in the US. Eurazeo also intends to support the company's shift towards a higher mix of recurring revenue through its proprietary consumables and surgical packs.
The acquisition of D.O.R.C. is part of the growth strategy of Eurazeo, which already has several external growth operations under its belt, notably Groupe CPK in 2017.
D.O.R.C., which reported an EBITDA margin of [members only] in 2018, is valued in this transaction at an EV/EBITDA multiple of [members only].
-> Deep-dive in Healthcare & Pharma market trends
Target
Headquartered in the Netherlands, D.O.R.C. is a global leader in ophthalmic surgery equipment. It specializes in the "posterior segment" of the eye (vitreoretinal surgery). Its flagship product, the EVA Nexus platform, is a dual-function system used for both cataract and retina surgeries, highly regarded by surgeons for its precision.
Ent. Value
€300–700M
Equity Value
[members only]
Multiples
EV / Revenue
2x–6x
EV / EBITDA
[members only]
EV / EBIT
[members only]
Historical Financials (EUR)
Other operations with D.O.R.C.
| Date | Acquirer | Target | Country | Sector |
|---|---|---|---|---|
| 08/2023 | CARL ZEISS MEDITEC | D.O.R.C. (DUTCH OPHTHALMIC RESEARCH CENTER) | NETHERLANDS | Medical Devices |
Other operations with Eurazeo
| Date | Acquirer | Target | Country | Sector |
|---|---|---|---|---|
| 10/2020 | EURAZEO / IK PARTNERS / RAISE | QUESTEL GROUP | FRANCE | Industry-Specific Software |
| 09/2020 | EURAZEO / FCDE (FONDS DE CONSOLIDATION ET DE DEVELOPPEMENT DES ENTREPRISES) | UTAC CERAM | FRANCE | TIC (Testing, Inspection, Certification) |
| 05/2017 | EURAZEO | GROUPE CPK (CARAMBAR POULAIN KREMA) | FRANCE | Food Products |
| 04/2016 | EURAZEO / MERIEUX EQUITY PARTNERS | NOVACAP | FRANCE | Specialty Chemicals |
| 03/2016 | EURAZEO | GLION INSTITUTE / LES ROCHES | SWITZERLAND | Education Providers |
| 11/2015 | EURAZEO | PLANET PAYMENT | IRELAND | Fintech & Payments |
| 09/2014 | EURAZEO | COLISÉE | FRANCE | Nursing Homes |
| 03/2014 | EURAZEO | DESIGUAL | SPAIN | Fashion & Apparel |
| 02/2014 | EURAZEO | VIGNAL GROUP | FRANCE | Auto Parts & Systems |
| 01/2014 | EURAZEO | ASMODEE GROUP | FRANCE | Consumer Products |
Similar deals in Life Sciences
| Date | Acquirer | Target | Country | Sector |
|---|---|---|---|---|
| 07/2019 | 3I | IONISOS | FRANCE | CDMO |
| 05/2019 | ARDIAN | SINTETICA | SWITZERLAND | Pharma & Biotech |
| 04/2019 | ICG / MERIEUX EQUITY PARTNERS | DOC GENERICI | ITALY | Generics / Labs |
| 12/2018 | MERCK & CO. | ANTELLIQ | FRANCE | Animal Health |
| 11/2018 | ARDIAN | NEOPHARMED GENTILI | ITALY | Generics / Labs |
| 10/2018 | GLANBIA | SLIMFAST | UNITED STATES | Nutrition & Dietary Supplements |
| 10/2018 | ASTORG | NEMERA | FRANCE | Medical Consumables |
| 10/2018 | BRIDGEPOINT | HTL BIOTECHNOLOGY | FRANCE | CDMO |
| 10/2018 | ARDIAN | INULA GROUP | BELGIUM | Pharma & Biotech |
| 08/2018 | DENTRESSANGLE | ACTEON | FRANCE | Medical Devices |
REFERENCES
Valuation range: EV €300–700M
Revenue range: €100–200M
EV/Revenue range: 2x - 6x
Note: This page provides detailed data on a private equity M&A transaction. Detailed and exact financial metrics for the acquisition of D.O.R.C. by Eurazeo are reserved for mynth community members. Register for free to unlock full data.
Authors: This transaction was contributed by a verified mynth contributor and cross-checked against available transaction documents and official company communications.
FAQ
What transaction does this page cover?
How was the acquisition of D.O.R.C. by Eurazeo valued, and what multiples were paid?
What was D.O.R.C.’s revenue at the time of the deal?
What sources support the information on this transaction?
What is mynth?